A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04869488 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: Fluzoparib
DRUG: Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets
DRUG: Fluzoparib Combined With Apatinib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.